Novartis have published preclinical information on its EGFR/VEGFR inhibitor AEE788 in the New England Journal of Medicine. IC50s were found to be 2nM for EGFR/VEGF receptor tyrosine kinases and 6 nM for ErbB2
Filed under: kinase | Tagged: AEE-788, AEE788, EGFR, ErbB-1, ErbB-2, ErbB1, ErbB2, Novartis, Preclinical, Research, VEGF | Comments Off
